Carl Zeiss Meditec (AFX) Price & Analysis

Compare

96 Followers

AFX Stock Chart & Stats

Day’s Range― - ―

52-Week Range€44.28 - €72.20

Previous CloseN/A

Volume39.86K

Average Volume (3M)146.43K

Market Cap

€4.29B

Enterprise Value€5.92B

Total Cash (Recent Filing)€51.45M

Total Debt (Recent Filing)€146.87M

Price to Earnings (P/E)27.1

Beta1.53

Next Earnings

Dec 11, 2025

EPS Estimate

0.68

Last Dividend Ex-Date

Mar 27, 2025

Dividend Yield1.39%

Share Statistics

EPS (TTM)0.41

Shares Outstanding89,440,570

10 Day Avg. Volume145,983

30 Day Avg. Volume146,427

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€59.36

Price Target Upside37.03% Upside

Rating ConsensusHold

Number of Analyst Covering11

Bulls Say, Bears Say

Bulls Say

Financial PerformanceCarl Zeiss Meditec released preliminary figures that were a substantial beat on topline and EBITA.

Market GrowthManagement mentions a clear upturn in refractive consumables in China, indicating a positive Chinese growth contribution.

Product LaunchApproval of Visumax 800 in China should drive better equipment revenue during H2.

Bears Say

Market HeadwindsThe China Refractive business, which historically had been an important driver of earnings growth and a key element of the equity thesis, slowed as a result of a soft macro environment and downtrading.

Profitability ConcernsThere may be questions over DORC's profitability as operating expenses are mounting.

Tariffs ImpactTariffs notably affect manufacturing in Germany and Singapore, which could impact guidance adjustments.

Carl Zeiss Meditec News

Carl Zeiss Meditec’s New Study on Cataract Surgery Outcomes: What Investors Need to Know

Carl Zeiss Meditec (($DE:AFX)) announced an update on their ongoing clinical study. Study Overview: Carl Zeiss Meditec is...

15d ago

AFX

Carl Zeiss Meditec’s Multifocal IOL Study: A Potential Game-Changer in Eye Care

Carl Zeiss Meditec (($DE:AFX)) announced an update on their ongoing clinical study. Study Overview: Carl Zeiss Meditec is...

21d ago

AFX

Hold Rating for Carl Zeiss Meditec Amid Optimistic Chinese Market Outlook and Operational Challenges

Dylan Van Haaften, an analyst from Stifel Nicolaus, maintained the Hold rating on Carl Zeiss Meditec (0DHC –...

3M ago

0DHC Earnings this Week: How Will it Perform?

Carl Zeiss Meditec (0DHC) is scheduled to report 2nd quarter earnings on 05/13/2025, before the market opens. Regarding...

3M ago

Cautious Hold on Carl Zeiss Meditec Amid Strong Q2 Results and Future Uncertainties

Analyst Dylan Van Haaften of Stifel Nicolaus maintained a Hold rating on Carl Zeiss Meditec (0DHC – Research...

4M ago

Optimistic Outlook on Carl Zeiss Meditec: Buy Rating Upgraded Amid Stabilizing Chinese Market and Visumax 800 Approval

Goldman Sachs analyst Richard Felton upgraded the rating on Carl Zeiss Meditec (0DHC – Research Report) to a...

5M ago

Hold Rating for Carl Zeiss Meditec Amidst Stabilization Challenges and Growth Opportunities

Stifel Nicolaus analyst Dylan Van Haaften maintained a Hold rating on Carl Zeiss Meditec (0DHC – Research Report)...

5M ago

Carl Zeiss Meditec (0DHC) Reveals Q1 Dividend: Here’s the Essential Information

Carl Zeiss Meditec (LSE: 0DHC) has declared, under its dividend policy, a yearly cash dividend in the amount...

6M ago

Is 0DHC a Buy, Before Earnings?

Carl Zeiss Meditec (0DHC) is scheduled to report 1st quarter earnings on 02/12/2025, before the market opens. Regarding...

6M ago

0DHC Upcoming Earnings Report: What to Expect?

Carl Zeiss Meditec (0DHC) is scheduled to report 4th quarter earnings on 12/11/2024, before the market opens. Regarding...

8M ago

AFX FAQ

What was Carl Zeiss Meditec’s price range in the past 12 months?

Carl Zeiss Meditec lowest stock price was €44.28 and its highest was €72.20 in the past 12 months.

What is Carl Zeiss Meditec’s market cap?

Carl Zeiss Meditec’s market cap is €4.29B.

When is Carl Zeiss Meditec’s upcoming earnings report date?

Carl Zeiss Meditec’s upcoming earnings report date is Dec 11, 2025 which is in 125 days.

How were Carl Zeiss Meditec’s earnings last quarter?

Carl Zeiss Meditec released its earnings results on Aug 07, 2025. The company reported €0.406 earnings per share for the quarter, missing the consensus estimate of €0.494 by -€0.088.

Is Carl Zeiss Meditec overvalued?

According to Wall Street analysts Carl Zeiss Meditec’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Carl Zeiss Meditec pay dividends?

Carl Zeiss Meditec pays a Annually dividend of €0.6 which represents an annual dividend yield of 1.39%. See more information on Carl Zeiss Meditec dividends here

What is Carl Zeiss Meditec’s EPS estimate?

Carl Zeiss Meditec’s EPS estimate is 0.68.

How many shares outstanding does Carl Zeiss Meditec have?

Carl Zeiss Meditec has 89,440,570 shares outstanding.

What happened to Carl Zeiss Meditec’s price movement after its last earnings report?

Carl Zeiss Meditec reported an EPS of €0.406 in its last earnings report, missing expectations of €0.494. Following the earnings report the stock price went down -9.524%.

Which hedge fund is a major shareholder of Carl Zeiss Meditec?

Currently, no hedge funds are holding shares in DE:AFX

Carl Zeiss Meditec Stock Smart Score

Neutral

Fundamentals

Return on Equity

7.48%

Trailing 12-Months

Asset Growth

18.98%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Carl Zeiss Meditec

Carl Zeiss Meditec AG is a leading global medical technology company that develops, manufactures, and distributes innovative solutions designed to improve quality of life. Operating within the healthcare and life sciences sectors, the company provides advanced technological solutions primarily for ophthalmology and microsurgery. Their comprehensive product portfolio includes diagnostic and surgical equipment for eye care professionals, as well as visualization solutions for microsurgical procedures across various medical disciplines.

Carl Zeiss Meditec (AFX) Earnings & Revenues

Historic Earnings Reports

AFX Stock 12 Month Forecast

Average Price Target

€59.36

▲(37.03% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"34":"€34","75":"€75","44.25":"€44.3","54.5":"€54.5","64.75":"€64.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":74,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€74.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":59.36,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€59.36</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":35.1,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€35.10</span>\n  </div></div>","useHTML":true}}],"tickPositions":[34,44.25,54.5,64.75,75],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,46.26,48.393846153846155,50.527692307692305,52.66153846153846,54.79538461538461,56.92923076923077,59.06307692307692,61.19692307692308,63.330769230769235,65.46461538461539,67.59846153846154,69.7323076923077,71.86615384615385,{"y":74,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,46.26,47.26769230769231,48.27538461538462,49.28307692307692,50.29076923076923,51.29846153846154,52.30615384615385,53.31384615384616,54.32153846153846,55.32923076923077,56.33692307692308,57.34461538461538,58.35230769230769,{"y":59.36,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,46.26,45.40153846153846,44.543076923076924,43.684615384615384,42.826153846153844,41.9676923076923,41.10923076923077,40.25076923076923,39.392307692307696,38.533846153846156,37.675384615384615,36.816923076923075,35.95846153846154,{"y":35.1,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":63.167,"date":1722470400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 10</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":64.257,"date":1725148800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":65.694,"date":1727740800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 9</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":56.776,"date":1730419200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":56.429,"date":1733011200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":45.103,"date":1735689600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":58.51,"date":1738368000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 26, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":59.501,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":58.75,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":60.1,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":54.85,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 24, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":56.45,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46.26,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >